Micron Stock Upgraded to Buy as New Street Sees $2 Trillion Valuation Potential 
UK Economy Posts Surprise June Growth as World Cup and Hot Weather Lift Activity 
Gold Prices Slip From Two-Month High as Inflation and Fed Outlook Drive Markets 
France Keeps Top Health Alert as Officials Brace for Another Heatwave 
LG, Nvidia Expand AI Partnership With Humanoid Robots, AI Factories 
Is space worth the cost? Accounting experts say its value can’t be found in spreadsheets 
Trump Imposes New US Tariffs on Drone Imports Over National Security Concerns 
Asian Stocks Rally as Cooling US Inflation Boosts Fed Rate Outlook 
Trump Administration Bars U.S. Travelers From Congo Flights Amid Ebola Outbreak 
GSK Reportedly Nears $9 Billion Acquisition of Cancer Drug Developer Nuvalent 
AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion 
Asian Currencies Edge Higher as Soft US Inflation Weighs on Dollar 
Thyssenkrupp Raises 2026 Profit Outlook as Steel and Materials Units Strengthen 
Google Pushes Gemini AI Overhaul as Sergey Brin Targets Model Supremacy 
Jared Isaacman Confirmed as NASA Administrator, Becomes 15th Leader of U.S. Space Agency 
FDA Investigates New Cyclospora Outbreak as U.S. Cases Continue to Rise 
Add as a preferred source on Google
South Korea’s JW Pharmaceutical has received a patent in Russia for a hair loss treatment currently under development, marking the first time that its candidate drug has been patented overseas.
The pharmaceutical firm received a patent for JW0061, its Wnt-targeted hair loss treatment, from Russia's Federal Service for Intellectual Property.
The patent covers a new heterocyclic inducer of the Wnt signaling pathway, including its base or isomer, and compositions containing it as an active ingredient.
JW has also submitted patent applications in more than ten nations, including the US, EU, Japan, and China.
JW0061 exhibits a novel method of action by directly binding to the GFRA1 protein in human hair dermal papilla cells, activating the Wnt signaling pathway. This is the first instance of a low-molecular-weight medication that describes the mechanism of hair growth that has been documented.
JW is now evaluating non-clinical toxicity in accordance with good laboratory practice with the intention of initiating clinical trials for JW0061 in the first half of 2024. Additionally, it collaborates on research projects with eminent dermatologists in the US.
JW plans to develop JW0061 as a new innovative drug that supplements or replaces existing hair loss treatments.
